Clinical Trial Update: Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations [Phase 2]

View source ↗

Summary

This Clinical Trial Update reports on a Phase 2 study of olaparib in patients with advanced glioma, cholangiocarcinoma, or other IDH1/IDH2-mutant solid tumors; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Glioblastoma
• Glioma
• Who Glioma

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Glioblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING